Summary of Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2022

Summary of Significant Accounting Policies

Schedule of reconciliation of the cash, cash equivalents and restricted cash amounts

	September 30, 2022		September 30, 2021
Cash and cash equivalents	$	77,916	$	105,321
Restricted cash, included in other assets		5,000		5,000
Cash, cash equivalents and restricted cash as presented on the Consolidated Statements of Cash Flows	$	82,916	$	110,321

Schedule of the Company's net sales by medical indication

	Three Months Ended
(In thousands)	September 30,
Medical Indication	2022		2021
Analgesic	$	3,424	$	5,314
Anti-Psychosis		2,620		3,715
Cardiovascular		10,882		14,100
Central Nervous System		20,794		22,785
Endocrinology		7,312		7,845
Gastrointestinal		7,942		15,240
Infectious Disease		5,069		12,515
Migraine		3,324		4,685
Respiratory/Allergy/Cough/Cold		1,202		3,114
Other		8,759		10,352
Contract manufacturing revenue		3,751		1,860
Total net sales	$	75,079	$	101,525

Summary of products which accounted for at least 10% of total net sales

	Three Months Ended
	September 30,
	2022		2021
Product 1	10	%	8	%
Product 2	4	%	10	%

Summary of customers which accounted for at least 10% of total net sales

	Three Months Ended
	September 30,
	2022		2021
Customer A	21	%	30	%
Customer B	20	%	20	%
Customer C	17	%	15	%